NO942707L - Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner - Google Patents

Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner

Info

Publication number
NO942707L
NO942707L NO942707A NO942707A NO942707L NO 942707 L NO942707 L NO 942707L NO 942707 A NO942707 A NO 942707A NO 942707 A NO942707 A NO 942707A NO 942707 L NO942707 L NO 942707L
Authority
NO
Norway
Prior art keywords
rubella
synthetic peptides
peptides suitable
vaccine
protein
Prior art date
Application number
NO942707A
Other languages
English (en)
Other versions
NO942707D0 (no
Inventor
Pele Chong
Shirley Gillam
Dawei Ou
Aubrey Tingle
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of NO942707D0 publication Critical patent/NO942707D0/no
Publication of NO942707L publication Critical patent/NO942707L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Syntetiske peptider har en aminosyresekvens som tilsva- rer minst en antigen determinant av minst et protein vanligvis et strukturert protein, spesielt El, E2 eller C-proteinene, hos rubella-virus (RV) blir brukt som sådan i hybrid eller kimerisk tandem T-B-form, i lipi- dert form, bundet til et bærermolekyl og/eller poly- merisert for å danne molekylære aggregater i vaksiner mot rubella. Analoger av peptider som er humane T-celle determinanter blir brukt til å behandle rubella-assosi- erte autoimmune sykdommer.
NO942707A 1992-01-20 1994-07-19 Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner NO942707L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201139A GB9201139D0 (en) 1992-01-20 1992-01-20 Synthetic peptides for a rubella vaccine
PCT/CA1993/000014 WO1993014206A2 (en) 1992-01-20 1993-01-20 Synthetic peptides for a rubella vaccine

Publications (2)

Publication Number Publication Date
NO942707D0 NO942707D0 (no) 1994-07-19
NO942707L true NO942707L (no) 1994-09-20

Family

ID=10708876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942707A NO942707L (no) 1992-01-20 1994-07-19 Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner

Country Status (10)

Country Link
US (1) US6037448A (no)
EP (1) EP0624198A1 (no)
JP (1) JPH07503133A (no)
AU (1) AU662954B2 (no)
CA (1) CA2128407C (no)
FI (1) FI943418A (no)
GB (1) GB9201139D0 (no)
NO (1) NO942707L (no)
RU (1) RU94040393A (no)
WO (1) WO1993014206A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427792A (en) * 1989-08-23 1995-06-27 Biochem Immunosystems, Inc. Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the E1 and E2 protein of rubella virus
AU1749597A (en) * 1996-01-19 1997-08-11 Virginia Mason Research Center Allele-specific peptide epitope strategy for vaccine development
CA2238660A1 (en) * 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
EP1432729B1 (en) * 2001-07-02 2008-11-12 Merrion Research III Limited Peyers's patch and/or m-cell targeting ligands
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP3077410B1 (en) * 2013-12-03 2021-02-03 Virometix AG Proline-rich peptides protective against s. pneumoniae
CN107098980A (zh) * 2017-06-28 2017-08-29 潍坊汉唐生物工程有限公司 一种检测风疹病毒抗体的融合蛋白及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206587A (en) * 1987-07-08 1989-01-11 London Biotechnology Ltd Rubella e1 glycoprotein antigens
US5164481A (en) * 1989-08-23 1992-11-17 Iaf Biochem International Inc. Peptides and analogues and mixtures thereof for detecting and eliciting antibodies to rubella virus

Also Published As

Publication number Publication date
CA2128407C (en) 2002-04-09
AU662954B2 (en) 1995-09-21
WO1993014206A2 (en) 1993-07-22
EP0624198A1 (en) 1994-11-17
CA2128407A1 (en) 1993-07-22
AU3341393A (en) 1993-08-03
FI943418A (fi) 1994-09-15
JPH07503133A (ja) 1995-04-06
NO942707D0 (no) 1994-07-19
WO1993014206A3 (en) 1993-10-28
RU94040393A (ru) 1996-11-10
FI943418A0 (fi) 1994-07-19
US6037448A (en) 2000-03-14
GB9201139D0 (en) 1992-03-11

Similar Documents

Publication Publication Date Title
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
AU591054B2 (en) Pre-S gene coded peptide hepatitis B immunogens, vaccines and diagnostics
DK0587780T3 (da) Smitstof, som forårsager Mystery Swine Disease, vaccinepræparater og diagnostiske sæt
GB2255093A (en) Hiv-1 core protein fragments
EP0243913A3 (en) Pre-s gene codes peptide hepatitis b immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
NO942707L (no) Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner
DE68925660D1 (de) Peptidfragmente von HIV
DK0661999T3 (da) Vacciner mod felint immundefekt virus (FIV)
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
NO319525B1 (no) Fremgangsmate for a danne et konjugat av et helt hemagglutinin,HA, protein av influensavirus samt fremgangsmate for fremstilling av et immunologisk preparat omfattende konjugatet.
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
ATE221786T1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
BRPI0009746B8 (pt) molécula de veículo contendo plasmídeo pg-pviii compreendendo uma seqúência que codifica uma parte de uma glicoproteína de lissavírus contendo pelo menos o sítio iii da glicoproteína de lissavírus mas não contendo o sítio ii, e, composição imunogênica
Balasa et al. Immunotargeting of thyroglobulin on antigen presenting cells abrogates natural tolerance in the absence of adjuvant
KR950701821A (ko) 피임 백신(contraceptive vaccine)
Rajnavölgyi Synthetic peptides in the search for T-and B-cell epitopes
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
BR9711809A (pt) Polipeptìdeo antigênico ou imunogênico, processos para tratar ou prevenir uma doença ou distúrbio em um indivìduo provocado por infecção com htlv-i, e com htlv-ii, para elicitar em um indivìduo a produção de anticorpos que especificamente ligam-se às proteìnas envelopes htlv-ii e htlv-i, e, para gerar uma resposta imune em um indivìduo
SE9202318D0 (sv) Nya peptider, diagnostiska antigen, anvaendning daerav, vacciner och medikamenter
ES1027961U (es) Soporte publicitario para carritos.
ES2065254A1 (es) Peptidos y vacunas sinteticas contra parvovirus canino y otros virus relacionados.